Clinical Testing of Pan-TRK Inhibitor Progresses Across Multiple Tumor Types

Newsfeed Image, Light Gray Text On Dark Gray Background
The pan-TRK inhibitor entrectinib (RXDX101) is being tested simultaneously in multiple locally advanced or metastatic solid tumor types as a treatment for patients harboring fusions involving the NTRK1/2/3, ROS1, or ALK genes.

The phase II, multicenter, STARTRK-2 basket trial (NCT02568267) stratifies patients based on their tumor type and genetic fusion. In 2 prior phase I trials, investigators tested entrectinib for safety and efficacy and demonstrated robust activity in multiple tumor types. The trials showed that the drug was well tolerated, with generally reversible and manageable low-grade adverse events Read more . . .